Acyclovir for Varicella Zoster Infection

Claude Fanelli; Fred R. Sattler; Henry H Balfour; Bonnie Bean; Oscar L. Laskin; Richard F. Ambinder; Joel D. Meyers; James C. Wade; John A. Zaia; Dorothee Aeppli; L. Edward Kirk; Anthony C. Segreti; Ronald E. Keeney

doi:10.1056/NEJM198404123101513

Acyclovir for Varicella Zoster Infection

Claude Fanelli, Fred R. Sattler, Henry H Balfour, Bonnie Bean, Oscar L. Laskin, Richard F. Ambinder, Joel D. Meyers, James C. Wade, John A. Zaia, Dorothee Aeppli, L. Edward Kirk, Anthony C. Segreti, Ronald E. Keeney

Laboratory Medicine and Pathology

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Abstract

To the Editor: Balfour et al. demonstrated in their placebo-controlled study that acyclovir prevented cutaneous or visceral dissemination of herpes zoster infection in immunocompromised patients, even if treatment was begun more than 72 hours after the first appearance of vesicles (June 16 issue).¹ However, the authors combined the results of therapy in patients with infection localized to a single dermatome and in those with generalized cutaneous disease before treatment. When we analyzed their results in these two groups separately, we found no statistical difference in outcome between patients treated with acyclovir and those given placebo, if treatment was begun after.

Original language	English (US)
Pages (from-to)	987-988
Number of pages	2
Journal	New England Journal of Medicine
Volume	310
Issue number	15
DOIs	https://doi.org/10.1056/NEJM198404123101513
State	Published - Apr 12 1984

Publisher link

10.1056/NEJM198404123101513

Find It

Find It at U of M Libraries

Cite this

@article{ec8d137942204d428e1ff78536dc1691,

title = "Acyclovir for Varicella Zoster Infection",

abstract = "To the Editor: Balfour et al. demonstrated in their placebo-controlled study that acyclovir prevented cutaneous or visceral dissemination of herpes zoster infection in immunocompromised patients, even if treatment was begun more than 72 hours after the first appearance of vesicles (June 16 issue).1 However, the authors combined the results of therapy in patients with infection localized to a single dermatome and in those with generalized cutaneous disease before treatment. When we analyzed their results in these two groups separately, we found no statistical difference in outcome between patients treated with acyclovir and those given placebo, if treatment was begun after.",

author = "Claude Fanelli and Sattler, {Fred R.} and Balfour, {Henry H} and Bonnie Bean and Laskin, {Oscar L.} and Ambinder, {Richard F.} and Meyers, {Joel D.} and Wade, {James C.} and Zaia, {John A.} and Dorothee Aeppli and Kirk, {L. Edward} and Segreti, {Anthony C.} and Keeney, {Ronald E.}",

year = "1984",

month = apr,

day = "12",

doi = "10.1056/NEJM198404123101513",

language = "English (US)",

volume = "310",

pages = "987--988",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "15",

}

TY - JOUR

T1 - Acyclovir for Varicella Zoster Infection

AU - Fanelli, Claude

AU - Sattler, Fred R.

AU - Balfour, Henry H

AU - Bean, Bonnie

AU - Laskin, Oscar L.

AU - Ambinder, Richard F.

AU - Meyers, Joel D.

AU - Wade, James C.

AU - Zaia, John A.

AU - Aeppli, Dorothee

AU - Kirk, L. Edward

AU - Segreti, Anthony C.

AU - Keeney, Ronald E.

PY - 1984/4/12

Y1 - 1984/4/12

N2 - To the Editor: Balfour et al. demonstrated in their placebo-controlled study that acyclovir prevented cutaneous or visceral dissemination of herpes zoster infection in immunocompromised patients, even if treatment was begun more than 72 hours after the first appearance of vesicles (June 16 issue).1 However, the authors combined the results of therapy in patients with infection localized to a single dermatome and in those with generalized cutaneous disease before treatment. When we analyzed their results in these two groups separately, we found no statistical difference in outcome between patients treated with acyclovir and those given placebo, if treatment was begun after.

AB - To the Editor: Balfour et al. demonstrated in their placebo-controlled study that acyclovir prevented cutaneous or visceral dissemination of herpes zoster infection in immunocompromised patients, even if treatment was begun more than 72 hours after the first appearance of vesicles (June 16 issue).1 However, the authors combined the results of therapy in patients with infection localized to a single dermatome and in those with generalized cutaneous disease before treatment. When we analyzed their results in these two groups separately, we found no statistical difference in outcome between patients treated with acyclovir and those given placebo, if treatment was begun after.

UR - http://www.scopus.com/inward/record.url?scp=0021319511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021319511&partnerID=8YFLogxK

U2 - 10.1056/NEJM198404123101513

DO - 10.1056/NEJM198404123101513

M3 - Letter

C2 - 6366564

AN - SCOPUS:0021319511

SN - 0028-4793

VL - 310

SP - 987

EP - 988

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 15

ER -

Acyclovir for Varicella Zoster Infection

Abstract

Publisher link

Find It

Other files and links

Fingerprint

Cite this